| 2
© 2024 Aprea Therapeutics, Inc. All Rights Reserved
Forward-Looking Statements
Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and strategic plans. We may, in some cases
use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or
other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The forward-looking statements are based on
current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions our management team might make or by known or unknown risks and
uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success and timing of our clinical
trials or other studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q. Forward-looking statements regarding our product candidates are also subject to additional risks and uncertainties, including without
limitation, with respect to: our dependence on additional financing to fund our operations and complete the development and commercialization of our product
candidates, and the risks that raising such additional capital may restrict our operations or require us to relinquish rights to our technologies or product candidates; our
limited history and preclinical status of the assets we acquired from Atrin Pharmaceuticals Inc.; our business plan or the likelihood of the successful implementation of
such business plan; the timing of initiation of planned clinical trials for our product candidates; the future success of such trials; the successful implementation of our
research and development programs and collaborations and the interpretation of the results and findings of such programs and collaborations and whether such results
are sufficient to support the future success of our product candidates; the success, timing and cost of our anticipated clinical trials for our current product candidates;
the timing of initiation, futility analyses, data presentation, reporting and publication and receipt of interim results (including, without limitation, any preclinical results or
data); any statements about our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical
development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within our control.
For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are
cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to
update such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by law or regulation. |